Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 20%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 60%Moderate 1 · 20%High 0 · 0%

Idebenone vs placebo

FVC (% predicted) Change from baseline · people with Duchenne muscular dystrophy and progressive respiratory decline

1 finding from 1 review

Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory… 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 64 participants
Low

Idebenone vs placebo

Frequency of hospitalisation for respiratory infection · people with Duchenne muscular dystrophy and progressive respiratory decline

The review found no eligible studies for this question.

1 finding from 1 review

Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Quality of life Assessed by: Pediatric Quality of Life Inventory, change from baseline (0 to 100; 0 = worst outcome, 100 = best outcome) · people with Duchenne muscular dystrophy and progressive respiratory decline

1 finding from 1 review

Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory… 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 63 participants
Moderate

Idebenone vs placebo

Serious adverse events · people with Duchenne muscular dystrophy and progressive respiratory decline

Idebenone showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory… 2021 · Cochrane Headline outcomes only
RR 0.42 [0.09, 2.04]
1 study · 66 participants
Low

Idebenone vs placebo

Non‐serious adverse events · people with Duchenne muscular dystrophy and progressive respiratory decline

Idebenone showed no clear difference in non‐serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory… 2021 · Cochrane Headline outcomes only
RR 1 [0.88, 1.13]
1 study · 66 participants
Low